SLC2A1 Variants and Diabetic Nephropathy

Association of Single Nucleotide Polymorphisms in the Gene Coding GLUT-1 and Diabetic Nephropathy in Brazilian Patients With Type 1 Diabetes Mellitus

Sponsors

Lead Sponsor: University of Sao Paulo General Hospital

Source University of Sao Paulo General Hospital
Brief Summary

Cells damaged by hyperglycemia are unable to downregulate glucose entrance in presence of high extracellular glucose resulting in intracellular activation of deleterious biochemical pathways. Expression of GLUT-1, the major glucose transporter in mesangial cells, is increased and participates in the induction of diabetic nephropathy. Variants in the gene encoding GLUT-1 (SLC2A1) have been associated to this diabetic complication. The aim of this study was to test whether polymorphisms in SLC2A1 confer susceptibility to diabetic nephropathy in Brazilian type 1 diabetes patients.

Detailed Description

In this study, 449 patients, included between October 2004 and October 2012, were sorted into three groups according to diabetic nephropathy stages: without (persistent normoalbuminuria, n=248), incipient (microalbuminuria, n=82) and overt diabetic nephropathy (macroalbuminuria or proteinuria or renal replacement therapy, n=119). Measurements of urinary albumin-to-creatinine ratio (ACR) or urinary albumin excretion rate (UAER) were used to define DN: patients with persistent normoalbuminuria (<30 mg/g creatinine or <20 μg/min) were classified as without DN (n=248); patients presenting persistent microalbuminuria (30-300 mg/g creatinine or 20-200 μg/min) were classified as having incipient DN (n=82); and patients presenting persistent macroalbuminuria (>300 mg/g creatinine or >200 µg/min), proteinuria (>500 mg/24 h) or renal replacement therapy were classified as having overt DN (n=119). Genotyping of polymorphisms was performed by Real Time PCR using fluorescent -labelled probes.

Overall Status Completed
Start Date October 2004
Completion Date October 2012
Primary Completion Date October 2012
Study Type Observational
Primary Outcome
Measure Time Frame
Plasmatic Creatinine Two years
Enrollment 449
Condition
Eligibility

Sampling Method: Probability Sample

Criteria:

Inclusion Criteria:

- Overt 10 years of Diabetes Mellitus

Exclusion Criteria:

- Patients presenting autoimmune diseases, HIV or HCV infections

- Patients with glomerular filtration rate < 60 mL min−1 1.73 m2 without diabetic retinopathy

Gender: All

Minimum Age: 11 Years

Maximum Age: N/A

Healthy Volunteers: No

Overall Official
Last Name Role Affiliation
Maria L Côrrea-Giannela, Doctor Principal Investigator Hospital Clínicas/Faculdade de Medicina da USP
Location
Facility: Faculdade de Medicina da USP
Location Countries

Brazil

Verification Date

January 2013

Responsible Party

Type: Sponsor

Has Expanded Access No
Condition Browse
Arm Group

Label: Withou Diabetic Nephropathy

Description: Patients who have persistent normoalbuminuria (<30 mg/g creatinine or <20 μg/min).

Label: Incipient Nephropathy

Description: Patients who have persistent microalbuminuria (30-300 mg/g creatinine or 20-200 μg/min).

Label: Overt Diabetic Nephropathy

Description: Patients who have persistent macroalbuminuria (>300 mg/g creatinine or >200 µg/min), proteinuria (>500 mg/24 h) or renal replacement therapy.

Study Design Info

Observational Model: Case-Only

Time Perspective: Cross-Sectional

Source: ClinicalTrials.gov